Symptomatic Effects of Chondroitin 4 and Chondroitin 6 Sulfate on Hand Osteoarthritis A Randomized, Double-Blind, Placebo-Controlled Clinical Trial at a Single Center

University Hospitals of Geneva and University of Geneva School of Medicine, Geneva, Switzerland.
Arthritis & Rheumatology (Impact Factor: 7.76). 11/2011; 63(11):3383-91. DOI: 10.1002/art.30574
Source: PubMed


To evaluate the symptomatic effects of highly purified chondroitin 4 and chondroitin 6 sulfate (CS) therapy in patients with osteoarthritis (OA) of the hand.
This investigator-initiated, single-center, randomized, double-blind, placebo-controlled clinical trial included 162 symptomatic patients with radiographic evidence of hand OA (American College of Rheumatology criteria). Inclusion criteria included patient's assessment of global spontaneous hand pain of at least 40 mm on a 0-100-mm visual analog scale (VAS) and functional impairment of at least 6 (0-30 scale) on the Functional Index for Hand OA (FIHOA) in the most symptomatic hand. Patients received either 800 mg of CS (n = 80 patients) or placebo (n = 82 patients) once daily for 6 months and were analyzed in an intent-to-treat approach. The two primary outcomes were the change in the patient's assessment of global spontaneous hand pain and in hand function (by FIHOA score) from baseline to month 6. Secondary outcomes were improvement in grip strength, duration of morning stiffness, acetaminophen consumption, and the investigator's global impression of treatment efficacy.
There was a significantly more pronounced decrease in the patient's global assessment of hand pain in the CS group than in the placebo group (difference VAS scores -8.7 mm; P = 0.016). Hand function improved significantly more in the CS group than in the placebo group (difference in FIHOA scores -2.14; P = 0.008). There was a statistically significant between-group difference in favor of CS for the duration of morning stiffness and for the investigator's global impression of treatment efficacy. Changes in grip strength, acetaminophen consumption, and safety end points were not significantly different between the two groups.
This study demonstrates that CS improves hand pain and function in patients with symptomatic OA of the hand and shows a good safety profile.

  • Source
    • "improvements in global hand pain and hand function. Most importantly , chondroitin-S was associated with a significant decrease in the duration of morning stiffness (Gabay et al., 2011). A randomized, double-blind, placebo-controlled study about the effect of a dietary supplement containing 1200 mg of GlcN.HCl, 60 mg of chondroitin-S and 45 mg of quercetin glycosides involved patients with symptomatic knee OA. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Oral supplementation of chondroitin sulphate plus glucosamine helps repair the articular surface in osteoarthritis. Chondroitin-S reduces the concentration of the pro-inflammatory cytokines and transcription factor involved in inflammation. GlcN.S enhances cartilage specific matrix components and prevents collagen degeneration in chondrocytes by inhibiting hydrolytic enzymes, and preventing the oxidation of lipids and proteins. Chondroitin-S plus GlcN.S are slow-acting drugs that alleviate pain and partly restore joint function in OA patients. Orally administered pharmaceutical-grade chondroitin-S plus GlcN.S stabilize the joint space narrowing and significantly decrease the number of patients with new erosive OA. They are safe and no adverse events have ever been reported; they are recommended by EULAR and OARSI. The cost/effectiveness of the oral chondroitin-S plus GlcN.S therapy derives from the reduction of costs for physiotherapy, and for gastroprotective and non-steroidal drugs. The synergistic association of these two world-widely preferred nutraceuticals is a step forward in the management of OA.
    Full-text · Article · Aug 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article provides a thorough review of erosive osteoarthritis of the hands, including the small changes observed over time in the epidemiology of the disease and the literature on genetic, etiopathogenic and clinical features. We also review the most useful complementary tests, the key points to include in the differential diagnosis, and end with an update on the treatment of this entity. Better understanding of this disease will help to achieve earlier diagnosis of its signs and symptoms, a more effective therapeutic approach, and closer monitoring of disease progression to avoid future disability.
    No preview · Article · Mar 2012 · Seminarios de la Fundación Española de Reumatología
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to assess whether chronic administration of chondroitin sulfate (CS) affects baseline expression of cytochrome P450 isoforms and impedes the decrease in expression and activity of CYP1A2 and CYP3A6 in rabbits with a turpentine-induced inflammatory reaction (TIIR). Seven groups of 5 rabbits, 3 control groups and 4 receiving 20 mg/kg/day of CS for 20 and 30 days, were used. The rabbits of 1 control group and 2 groups receiving CS had a TIIR; finally, the rabbits of one of the control groups remained in the animal facilities for 30 days to assess the effect of time and environment on cytochrome P450. In control rabbits, intake of CS for 20 and 30 days did not affect CYP3A6, CYP1A2 and NADPH cytochrome P450 reductase (CPR) mRNA, protein expression and activity. Compared with control rabbits, the TIIR not only reduced mRNA, protein expression and activity of CYP3A6 and CYP1A2 but also that of CPR. In rabbits with TIIR, CS prevented the decrease of CYP3A6 expression but not the reduction in activity. CS did not impede TIIR-induced down-regulation of CYP1A2. Hepatic NO() concentrations and NF-κB nuclear translocation were increased by the TIIR, effect reversed by CS. In vitro, in hepatocytes, CS did not alter the expression and activity of CYP3A6, CYP1A2, and CPR. In conclusion, oral CS elicits a systemic effect but does not affect CYP1A2, CYP3A6, and CPR in control rabbits, although in rabbits with TIIR, CS prevents CYP3A6 protein down-regulation but not that of CYP1A2.
    No preview · Article · May 2012 · Carbohydrate research
Show more